In today’s difficult circumstances, it is my responsibility to provide an open and transparent update on the expected effects of COVID-19 on Fidelis’ services. Our work is closely related to clinical sites and they are the ones that will be at the forefront of this global challenge in the weeks to come. We are fully aware that this will limit the extent to which the sites will be able to perform more than what is necessary to ensure the health and safety of patients and to support local authorities in their efforts to limit the impact of the pandemic.
Fidelis has been developing a wide network of clinical sites and collection facilities across multiple countries precisely in order to be as flexible as possible. We are in a continuous communication with our collaborators and will act swiftly to ensure minimal impact to our operations and ability to provide the best service to our customers by working with least affected sites, while not interfering with their priorities.
The most important asset we have are our employees, partnering sites and investigators and we are closely following the dynamic situation in order to protect our people, their immediate families, and collaborators. We have implemented measures to limit additional risks and are strictly following local and regional recommendations from the relevant authorities. These precautions include screening measures preventing collection of samples from donors showing with potential symptoms in order to ensure their own safety, the safety of our staff and customers.
As always, we are striving to support our research partners. We are looking forward to the better days ahead and to resuming operations back to normal under the safest circumstances. We will provide continuous updates as the situation develops. We remain available for contact to address specific ongoing projects.
CEO, Fidelis Research